Literature DB >> 19399919

Estimating ethnic differences in self-reported new use of antidepressant medications: results from the Multi-Ethnic Study of Atherosclerosis.

Joseph A C Delaney1, Bruce E Oddson, Robyn L McClelland, Bruce M Psaty.   

Abstract

INTRODUCTION: There is evidence that the utilization of antidepressant medications (ADM) may vary between different ethnic groups in the United States population.
METHODS: The Multi-Ethnic Study of Atherosclerosis (MESA) is a population-based prospective cohort study of 6814 US adults from 4 different ethnic groups. After excluding baseline users of ADM, we examined the relation between baseline depression and new use of ADM for 4 different ethnicities: African-Americans (n = 1822), Asians (n = 784) Caucasians (n = 2300), and Hispanics (n = 1405). Estimates of the association of ethnicity and ADM use were adjusted for age, study site, gender, Center for Epidemiologic Studies Depression Scale (CES-D), alcohol use, smoking, blood pressure, diabetes, education, and exercise. Non-random loss to follow-up was present and estimates were adjusted using inverse probability of censoring weighting (IPCW).
RESULTS: Of the four ethnicities, Caucasian participants had the highest rate of ADM use (12%) compared with African-American (4%), Asian (2%), and Hispanic (6%) participants. After adjustment, non-Caucasian ethnicity was associated with reduced ADM use: African-American (HR: 0.42; 95% Confidence Interval (CI): 0.31-0.58), Asian (HR: 0.14; 95%CI: 0.08-0.26), and Hispanic (HR: 0.47; 95%CI: 0.31-0.65). Applying IPCW to correct for non-random loss to follow-up among the study participants weakened but did not eliminate these associations: African-American (HR: 0.48; 95%CI: 0.30-0.57), Asian (HR: 0.23; 95%CI: 0.13-0.37), and Hispanic (HR: 0.58; 95%CI: 0.47-0.67).
CONCLUSION: Non-Caucasian ethnicity is associated with lower rates of new ADM use. After IPCW adjustment, the observed ethnicity differences in ADM use are smaller although still statistically significant. (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19399919      PMCID: PMC2844249          DOI: 10.1002/pds.1751

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  25 in total

1.  Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.

Authors:  M A Hernán; B Brumback; J M Robins
Journal:  Epidemiology       Date:  2000-09       Impact factor: 4.822

2.  Missing confounding data in marginal structural models: a comparison of inverse probability weighting and multiple imputation.

Authors:  Erica E M Moodie; Joseph A C Delaney; Geneviève Lefebvre; Robert W Platt
Journal:  Int J Biostat       Date:  2008       Impact factor: 0.968

3.  Covariance analysis of censored survival data.

Authors:  N Breslow
Journal:  Biometrics       Date:  1974-03       Impact factor: 2.571

4.  The acceptability of treatment for depression among African-American, Hispanic, and white primary care patients.

Authors:  Lisa A Cooper; Junius J Gonzales; Joseph J Gallo; Kathryn M Rost; Lisa S Meredith; Lisa V Rubenstein; Nae-Yuh Wang; Daniel E Ford
Journal:  Med Care       Date:  2003-04       Impact factor: 2.983

5.  Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. The Cardiovascular Health Study Collaborative Research Group.

Authors:  B M Psaty; M Lee; P J Savage; G H Rutan; P S German; M Lyles
Journal:  J Clin Epidemiol       Date:  1992-06       Impact factor: 6.437

Review 6.  Relationship of anxiety and depression.

Authors:  A Frances; D Manning; D Marin; J Kocsis; K McKinney; W Hall; M Kline
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

7.  Depressed mood and major depressive disorder in two ethnic groups.

Authors:  J M Golding; R I Lipton
Journal:  J Psychiatr Res       Date:  1990       Impact factor: 4.791

8.  Improving care for minorities: can quality improvement interventions improve care and outcomes for depressed minorities? Results of a randomized, controlled trial.

Authors:  Jeanne Miranda; Naihua Duan; Cathy Sherbourne; Michael Schoenbaum; Isabel Lagomasino; Maga Jackson-Triche; Kenneth B Wells
Journal:  Health Serv Res       Date:  2003-04       Impact factor: 3.402

9.  Prescriber intent, off-label usage, and early discontinuation of antidepressants: a retrospective physician survey and data analysis.

Authors:  Jay M Pomerantz; Stan N Finkelstein; Ernst R Berndt; Amy W Poret; Leon E Walker; Robert C Alber; Vidya Kadiyam; Mitali Das; David T Boss; Thomas H Ebert
Journal:  J Clin Psychiatry       Date:  2004-03       Impact factor: 4.384

10.  Multi-Ethnic Study of Atherosclerosis: objectives and design.

Authors:  Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy
Journal:  Am J Epidemiol       Date:  2002-11-01       Impact factor: 4.897

View more
  9 in total

1.  A Canadian Primary Care Sentinel Surveillance Network Study Evaluating Antidepressant Prescribing in Canada From 2006 to 2012.

Authors:  Rachael Morkem; David Barber; Tyler Williamson; Scott B Patten
Journal:  Can J Psychiatry       Date:  2015-12       Impact factor: 4.356

2.  Association of subsyndromal and depressive symptoms with inflammatory markers among different ethnic groups: the multi-ethnic study of atherosclerosis (MESA).

Authors:  Álvaro Camacho; Britta Larsen; Robyn L McClelland; Cindy Morgan; Michael H Criqui; Mary Cushman; Matthew A Allison
Journal:  J Affect Disord       Date:  2014-04-19       Impact factor: 4.839

Review 3.  Precision medicine: does ethnicity information complement genotype-based prescribing decisions?

Authors:  Rashmi R Shah; Andrea Gaedigk
Journal:  Ther Adv Drug Saf       Date:  2017-12-01

4.  Factors associated with antidepressant use among low-income racially and ethnically diverse patients with type 2 diabetes.

Authors:  Caroline A Presley; Richard O White; Aihua Bian; Jonathan S Schildcrout; Russell L Rothman
Journal:  J Diabetes Complications       Date:  2019-07-15       Impact factor: 2.852

5.  Antidepressant Use and Subclinical Measures of Atherosclerosis: The Multi-Ethnic Study of Atherosclerosis.

Authors:  Álvaro Camacho; Robyn L McClelland; Joseph A Delaney; Matthew A Allison; Bruce M Psaty; Dena E Rifkin; Stephen R Rapp; Moyses Szklo; Murray B Stein; Michael H Criqui
Journal:  J Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.153

6.  Baseline depressive symptoms are not associated with clinically important levels of incident hypertension during two years of follow-up: the multi-ethnic study of atherosclerosis.

Authors:  Joseph A C Delaney; Bruce E Oddson; Holly Kramer; Steven Shea; Bruce M Psaty; Robyn L McClelland
Journal:  Hypertension       Date:  2010-01-11       Impact factor: 10.190

Review 7.  Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis.

Authors:  Greta Wozniak; Aikaterini Toska; Maria Saridi; Odysseas Mouzas
Journal:  Med Sci Monit       Date:  2011-09

8.  The importance of censoring in competing risks analysis of the subdistribution hazard.

Authors:  Mark W Donoghoe; Val Gebski
Journal:  BMC Med Res Methodol       Date:  2017-04-04       Impact factor: 4.615

9.  Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: a cohort study in the French national health insurance database.

Authors:  Anke Neumann; Géric Maura; Alain Weill; Philippe Ricordeau; François Alla; Hubert Allemand
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-12-02       Impact factor: 2.890

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.